MindWalk Holdings Corp (HYFT) Stock Analysis

$1.340

-0.048 (-3.60%)At close

Loading chart…

High: 1.390
Open: 1.370
VWAP: 1.35
Vol: 55.68K
Mkt Cap: —
Low: 1.320
Amount: 75.17K
EV/EBITDA, TTM: -2.34

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

www.mindwalkai.com

AI analysis of MindWalk Holdings Corp (HYFT)

buy

MindWalk Holdings Corp (HYFT) is a good buy right now due to its recent inclusion in the Russell 3000 Index, which is expected to enhance visibility and attract institutional investors. The stock has shown a 52% year-over-year revenue growth in Q3, reaching $4.2 million, and a gross margin improvement to 60.63% in Q4 2026. However, the main risk is the negative earnings per share (EPS) of -0.08, indicating ongoing losses, but the potential for recovery is strong given the positive market sentiment and analyst support.

Valuation Metrics

The current forward P/E ratio for MindWalk Holdings Corp (HYFT) is 0.00, compared to its 5-year average forward P/E of -29.94.

Forward P/E

Strongly Overvalued

5Y Average P/E

-29.94

Current P/E

0.00

Overvalued

-18.15

Undervalued

-41.74

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.39

Current EV/EBITDA

-2.34

Overvalued

-0.09

Undervalued

-4.69

Forward P/S

Undervalued

5Y Average P/S

4.18

Current P/S

2.62

Overvalued

5.63

Undervalued

2.73

Events Timeline

2026-07-23 (ET)